Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Introduction. The comorbidities of hypertension, diabetes mellitus, obesity, hyperlipidemia, and metabolic syndrome are common in patients with heart failure (HF) and affect clinical outcomes. Interestingly, although these comorbidities are associated with the development of incident HF in the general population, in patients with established HF, their contributory roles to clinical outcomes are not predictable, and their management is quite challenging. Recent American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines have addressed the role of lifestyle modification,4 treatment of blood cholesterol,5 and management of overweight and obesity. Eighth Joint National Committee addressed the management of hypertension. However, these guidelines did not specifically address the management of such comorbidities in patients with HF. Similarly, the most recent ACCF/AHA HF practice guidelines. HF in broad terms, but again, specific and detailed recommendations on how to manage hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome are lacking. The intent of this AHA scientific statement is to summarize data relevant to contributory risk and to provide guidance on the management of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in the development and prognosis of HF to provide recommendations (Table 1) and to foster communication between physicians and other healthcare professionals and patients on the management of these comorbidities. Recommendations in this document are based on published studies and the multidisciplinary expertise of the writing group and harmonized with published practice guidelines from the ACC/AHA4–6,8–1. Table 1. Applying Classification of Recommendations and Level of Evidence. Hypertension and HFHypertension is a worldwide epidemic; in many countries, 5. Hypertension is defined as a repeatedly elevated blood pressure (BP) exceeding 1. Hg. The prevalence of hypertension is steadily increasing, even with the expanded use of antihypertensive medications. It is widely recognized that hypertension is associated with increased cardiovascular and all- cause mortality independently of other risk factors. Specific HF mortality attributable to hypertension is probably underreported because of the competing adjudication for stroke or myocardial infarction (MI) at the end of the spectrum of hypertensive cardiovascular death. Hypertension Plays a Significant Role in the Development of HFElevated levels of diastolic BP and especially systolic BP (SBP) are major risk factors for the development of HF. One of the most impactful observations from the Framingham cohort was that the cumulative incidence of HF was significantly higher in patients with hypertension. The concept of lifting weights one day and doing cardio and abs the next is outdated. The current standard in fitness is metabolic training which harnesses the power.![]() Figure 1) Among 5. HF had hypertension antedating the development of HF, underlining that in the majority of patients with HF, hypertension was a contributing cause. The hazard ratios (HRs) for developing HF in hypertensives compared with normotensives were 2- fold higher in men and 3- fold higher in women. It should be noted that the risk associated with hypertension may be accentuated through its confounding effect on ischemic heart disease and other cardiovascular outcomes such as stroke. Furthermore, these studies predate current HF management strategies and guidelines and may no longer reflect the risk in the current population treated for hypertension. However, they underscore the importance of hypertension as a cause of HF when left untreated. The residual lifetime risk for hypertension for middle- aged and elderly individuals in the United States is 9. HF. Figure 1. Cumulative incidence of heart failure, adjusted for death as a competing risk, by baseline systolic blood pressure (SBP) categories of < 1. Reprinted from Butler et al. ![]() BMJ Publishing Group Ltd. In placebo- controlled trials, although the relative risks of total major cardiovascular events were reduced by regimens based on angiotensin- converting enzyme (ACE) inhibitors (2. HF was reduced significantly by ACE inhibitors but not calcium antagonists. Greater risk reductions were produced by treatment regimens that targeted lower BP goals than those targeting relatively higher BP goals. Treatment. Treatment of Hypertension in Patients at Risk for Developing HFGoals of Treatment of Hypertension to Prevent HFPatients with hypertension are at high risk for developing HF (stage A), and their BP should be controlled in accordance with contemporary guidelines to lower the risk of HF (Level of Evidence A8; Table 2). According to the recently published 2. BP in adults,7 the goal for treatment of BP has been identified as < 1. Hg for patients who are < 6. Hg for patients . It should be noted that this last recommendation of a higher target for patients . The most recent 2. BP in adults recommends that in the general nonblack population, including those with diabetes mellitus, the initial antihypertensive treatment should include a thiazide- type diuretic, a calcium channel blocker, an ACE inhibitor, or an angiotensin receptor blocker (ARB). Each of these 4 drug classes recommended by the writing group yielded comparable effects on overall mortality, cardiovascular (excluding HF), cerebrovascular, and kidney outcomes. However, the effects of these drug classes on HF differ. Treatment with a thiazide- type diuretic or an ACE inhibitor has been shown to be more effective than treatment with a calcium channel blocker in improving HF outcomes. Although the writing committee recognized that improved HF outcome was an important finding that should be considered in the selection of a drug for initial therapy for hypertension, the panel did not conclude that it was compelling enough to preclude the use of the other drug classes for initial therapy. The panel also acknowledged that the evidence supported BP control, rather than a specific agent used to achieve that control, as the most relevant consideration for their recommendation. Supporting this, historically, most antihypertensive drugs have demonstrated comparable cardiovascular efficacy and safety. Specifically, diuretic- based antihypertensive therapies have been shown to prevent HF in a wide range of target populations as first- line therapy. ![]() Dukan Diet » Introduction » Science behind the Dukan Diet: Ketosis, Carbohydrate Restriction and Metabolic Effects. Science behind the Dukan Diet: Ketosis. Metabolic syndrome, a cluster of conditions, raises your odds of heart attack or stroke. The comorbidities of hypertension, diabetes mellitus, obesity, hyperlipidemia, and metabolic syndrome are common in patients with heart failure (HF) and affect. Additionally, low- dose diuretics have been shown to be more effective as a first- line treatment for preventing the development of HF compared with ACE inhibitors, . ACE inhibitors have also been shown to be very effective in the prevention of HF,1. LV) systolic dysfunction or patients after MI. Likewise, ARBs have been shown to reduce the incidence of HF, especially in patients with hypertension and type 2 diabetes mellitus and nephropathy. However, calcium channel blockers appear to be somewhat less efficacious than the above agents for preventing HF. There are inadequate data to determine whether this is true only for dihydropyridine calcium channel blockers or whether it is true of the entire class of drugs. Regarding . Thus, in patients with a recent or remote history of MI or acute coronary syndrome and reduced ejection fraction (EF), ACE inhibitors. ARBs if the patient is ACE inhibitor intolerant. HF and reduce mortality. Similarly, in patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, . Former guidelines and position papers differ significantly in such threshold definitions and lack strong evidence for treatment targets of hypertension in HF. Therefore, the optimal BP target for the treatment of hypertension in patients with HF is not firmly established. The 2. 00. 7 AHA scientific statement on the treatment of hypertension in the prevention and management of ischemic heart disease recommended a target BP of < 1. Hg in patients with HF. Similarly, the 2. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke”9 identified the BP treatment goal as < 1. Hg if HF was present. T3 and T4 are critical for metabolic functions that include metabolic rate, and the growth and smooth functionality of almost all of the body ![]() ![]() However, these recommendations were empirical, not supported by trial evidence. Furthermore, there is concern about potential adverse outcomes with BP lowering that is too aggressive, which was further supported by the change to a higher BP threshold of 1. Hg in patients < 6. Hg in patients . The lack of definitive BP targets in patients with existing HF notwithstanding, treatment of HF is usually the main focus of the initial treatment of patients with established HF, and the standard treatment of HF usually lowers BP. This is supported by the observation that SBP has usually been lowered to a normal range of 1. Hg in most successful HF treatment trials with HF medications. After optimization of HF treatment, if BP is not controlled, further treatment strategies targeting both BP and HF can be used. It should also be noted that the BP- lowering effects of HF medications may relate to the baseline BP; that is, there may be a greater BP- lowering effect in patients with a higher baseline BP. However, the beneficial effects of the HF medications are usually independent of the baseline BP or changes in BP and do not vary according to baseline BP or reductions in SBP levels. Medication Choices for the Treatment of Hypertension in Patients With HFCurrently, there are no randomized, large- scale trials comparing the effectiveness of different antihypertensive medications targeting optimal treatment of BP solely in patients with hypertension and established HF. Thus, most evidence comes from hypertension clinical trials that have not excluded patients with a history of HF. In patients with established HF, drugs that have been shown to improve outcomes for patients with HF generally also lower BP. Tortoise Trust Web - Emergency Symptoms! RECOGNISING VETERINARY EMERGENCIESEarly. By. Nadine Gill. With continuing. There are still far too many, however, who could have been. They felt a loss of breath, pain weighing on their chest. It only takes a browse through any. Does anybody know why my turtle is laying on a rock. My tortoise has been in an accident, and. What should I do?” And in their search for advice, the. I get phone. calls, e- mails and, on occasion, even letters. And when I hear the symptoms. Get. the animal to a specialist vet, without delay”. Knowing the warning signs. In such cases, every minute counts: 1. Edema. (see above). Possible. causes: If arises suddenly, could be related to renal or pulmonary disease. Possible causes: Vitamin A deficiency or excess, or bacterial. Possible causes: These symptoms are indicative of critical. Indicates dangerously low red blood count. Possible causes. Severe parasitic infection, internal hemorrhaging, renal or liver disease. Possible. causes: Could be symptomatic of renal disease, spinal injury or metabolic. In females suspect egg- retention problem and x- ray to confirm or. The following are symptomatic of serious conditions that. Suspect eye or ear infection (shown below: box. Could have localized swelling. Could be the. result of numerous conditions that require proper diagnosis. Could. be due to nutritional deficiencies, parasite problems, possible thyroid- related. As you can see, some symptoms may occur with various forms. Swollen eyes are often found in conjunction with an ear abscess. A deficiency, or a purely local. Locomotion difficulties and weakness are symptomatic of any number. It isn’t surprising that veterinarians themselves avoid. Certain symptoms may indeed. This. would include a physical examination, any necessary diagnostic tests, and a. The early warning signs of illness are sometimes quite. Remember, early treatment saves lives, both for people - and. Highfield/Tortoise Trust.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |